Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma
Authors:
- Lois B. TravisLTLois B. Travis
- Deirdre HillDHDeirdre Hill
- Graça M. DoresGDGraça M. Dores
- Mary GospodarowiczMGMary Gospodarowicz
- Flora E. van LeeuwenFLFlora E. van Leeuwen
- Eric HolowatyEHEric Holowaty
- Bengt GlimeliusBGBengt Glimelius
- Michael AnderssonMAMichael Andersson
- Eero PukkalaEPEero Pukkala
- Charles F. LynchCLCharles F. Lynch
- David PeeDPDavid Pee
- Susan A. SmithSSSusan A. Smith
Open Access
- 5 October 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 97 (19) , 1428-1437
Abstract
Background: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age and calendar year of HL diagnosis, HL treatment information, population breast cancer incidence rates, and competing causes of death. Methods: Relative risks of breast cancer for categories defined by radiation dose to the chest (0, 20–Results: Cumulative absolute risks of breast cancer increased with age at end of follow-up, time since HL diagnosis, and radiation dose. For an HL survivor who was treated at age 25 years with a chest radiation dose of at least 40 Gy without alkylating agents, estimated cumulative absolute risks of breast cancer by age 35, 45, and 55 years were 1.4% (95% confidence interval [CI] = 0.9% to 2.1%), 11.1% (95% CI = 7.4% to 16.3%), and 29.0% (95% CI = 20.2% to 40.1%), respectively. Cumulative absolute risks were lower in women treated with alkylating agents. Conclusions: Breast cancer projections varied considerably by type of HL therapy, time since HL diagnosis, and age at end of follow-up. These estimates are applicable to HL survivors treated with regimens of the past and can be used to counsel such patients and plan management and preventive strategies. Projections should be used with caution, however, in patients treated with more recent approaches, including limited-field radiotherapy and/or ovary-sparing chemotherapy.Keywords
This publication has 36 references indexed in Scilit:
- Breast Cancer Risks for BRCA1/2 CarriersScience, 2004
- High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin’s Disease: Report From the Late Effects Study GroupJournal of Clinical Oncology, 2003
- Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s DiseaseJournal of Clinical Oncology, 2003
- Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsBlood, 2002
- Breast Cancer Screening in Women Previously Treated for Hodgkin’s Disease: A Prospective Cohort StudyJournal of Clinical Oncology, 2002
- Quantitative Classification of Mammographic Densities and Breast Cancer Risk: Results From the Canadian National Breast Screening StudyJNCI: Journal of the National Cancer Institute, 1995
- Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphomaAnnals of Hematology, 1994
- Breast Cancer After Treatment of Hodgkin's DiseaseJNCI: Journal of the National Cancer Institute, 1993
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989
- Female Reproductive Potential after Treatment for Hodgkin's DiseaseNew England Journal of Medicine, 1981